Anti-TATA binding protein TBP antibody (ab70009)
- Product nameAnti-TATA binding protein TBP antibodySee all TATA binding protein TBP primary antibodies ...
- DescriptionRabbit polyclonal to TATA binding protein TBP
- Tested applicationsWB, ELISA more details
- Species reactivityReacts with: Mouse, Rat, Human
Synthetic peptide (Human) from an internal region
- Positive control293 cell extract
- Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
- Storage bufferPreservative: 0.02% Sodium Azide
Constituents: 50% Glycerol, PBS (without Mg2+ and Ca2+), 150mM Sodium chloride, pH 7.4
- Concentration information loading...
- PurityImmunogen affinity purified
- Clonality Polyclonal
- Epigenetics and Nuclear Signaling
- Polymerase associated factors
- Pol II Transcription
Our Abpromise guarantee covers the use of ab70009 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||WB: 1/500 - 1/1000. Detects a band of approximately 38 kDa (predicted molecular weight: 38 kDa).|
- FunctionGeneral transcription factor that functions at the core of the DNA-binding multiprotein factor TFIID. Binding of TFIID to the TATA box is the initial transcriptional step of the pre-initiation complex (PIC), playing a role in the activation of eukaryotic genes transcribed by RNA polymerase II. Component of the transcription factor SL1/TIF-IB complex, which is involved in the assembly of the PIC (preinitiation complex) during RNA polymerase I-dependent transcription. The rate of PIC formation probably is primarily dependent on the rate of association of SL1 with the rDNA promoter. SL1 is involved in stabilization of nucleolar transcription factor 1/UBTF on rDNA.
- Tissue specificityWidely expressed, with levels highest in the testis and ovary.
- Involvement in diseaseDefects in TBP are the cause of spinocerebellar ataxia type 17 (SCA17) [MIM:607136]. Spinocerebellar ataxia is a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCA17 is an autosomal dominant cerebellar ataxia (ADCA) characterized by widespread cerebral and cerebellar atrophy, dementia and extrapyramidal signs. The molecular defect in SCA17 is the expansion of a CAG repeat in the coding region of TBP. Longer expansions result in earlier onset and more severe clinical manifestations of the disease.
- Sequence similaritiesBelongs to the TBP family.
- Cellular localizationNucleus.
- GTF2D antibodyGTF2D1 antibodyHDL4 antibody
- MGC117320 antibodyMGC126054 antibodyMGC126055 antibodySCA17 antibodyTATA binding factor antibodyTATA box factor antibodyTATA sequence binding protein antibodyTATA sequence-binding protein antibodyTATA-binding factor antibodyTATA-box binding protein N-terminal domain antibodyTATA-box factor antibodyTATA-box-binding protein antibodyTBP antibodyTBP_HUMAN antibodyTFIID antibodyTranscription initiation factor TFIID TBP subunit antibody
Anti-TATA binding protein TBP antibody images
All lanes : Anti-TATA binding protein TBP antibody (ab70009)
Lane 1 : 293 cells
Lane 2 : 293 cells with blocking peptide
Predicted band size : 38 kDa
References for Anti-TATA binding protein TBP antibody (ab70009)
This product has been referenced in:
- Ma J et al. Morphine disrupts interleukin-23 (IL-23)/IL-17-mediated pulmonary mucosal host defense against Streptococcus pneumoniae infection. Infect Immun 78:830-7 (2010). WB ; Mouse . Read more (PubMed: 19995896) »